Operations commence at Wasdell Group’s EU headquarters

8 Jul 2019

The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

The Wasdell Group has announced its new state-of-the-art facility in Dundalk, Ireland has received its Manufacturer’s/Importation Authorisation licence (MIA) from the Health Products Regulatory Authority (HPRA).

Operations commence at Wasdell Group’s EU headquarters

The new EU headquarters, which are a result of a significant investment in a greenfield site at the new IDA Technology & Science Park, Dundalk, has now commenced operations.

The 90,000 sq. ft. facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

With building work commencing in September 2018 the facility is thought to be the fastest custom-built site to achieve cGMP approval.

Vincent Dunne, CEO said: “This is another significant milestone for Wasdell, and I am extremely proud of our team and the efforts made to open this facility.

“We are seeing growing demand for our services, especially from companies that wish to outsource their entire product lifecycle from clinical services and EU launch to manufacturing, packaging and distribution. The new facility strengthens our offering, allowing us to further support our customers.”

Wasdell also has facilities in Swindon, Northampton and Newcastle, UK, and has grown to be an industry leader by offering flexible and agile solutions to its growing customer base. The Ireland site will support the company’s ongoing growth, whilst also allowing Wasdell to cement its presence in Europe in preparation for Brexit.

Dunne continued: “With over 75% of our turnover as export business, our new facility will serve our large client base in Europe and better support our growing US customer portfolio as they look to outsource their European supply chain operations from clinical projects to routine supply.”

“We have onboarded an experienced team who are well-versed in overseeing rigorous quality standards and ensuring operational efficiency to improve customer experience and enable our promise to deliver safe, high quality products to patients in Europe.”

The site also underwent a successful HPRA inspection in late 2018, which granted permission to perform QP batch certification and release of pharmaceutical products into Europe, further supporting Wasdell’s Brexit preparations.

Read More

Related news

Colorcon launches new $50 million VC Fund

Colorcon launches new $50 million VC Fund

17 Sep 2019

The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services.

Read more 
M2i Life Sciences completes a historic fundraising of 60 million Euros

M2i Life Sciences completes a historic fundraising of 60 million Euros

16 Sep 2019

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

Read more 
Daiichi Sankyo releases new generic formulation for sustained cancer pain treatment

Daiichi Sankyo releases new generic formulation for sustained cancer pain treatment

13 Sep 2019

New formulation of oxycodone hydrochloride contains the narcotic antagonist naloxone in order to prevent abuse.

Read more 
Mallinckrodt to sell BioVectra for $250 million

Mallinckrodt to sell BioVectra for $250 million

11 Sep 2019

Transaction continues to advance Mallinckrodt's strategic focus on branded, high-growth biopharmaceuticals by monetizing a non-core business.

Read more 
Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Catalent to open new clinical supply facility in San Diego

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more